Immune activation in patients infected with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 18, Issue 18, 2002, Pages 1351-1355

  Almeida, Coral Ann M ^a,b   Price, Patricia ^a,b   French, Martyn A H ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; VIRUS RNA;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; VIRUS REPLICATION;

ADP-RIBOSYL CYCLASE; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, CD; ANTIGENS, CD38; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HLA-DR ANTIGENS; HUMANS; IMMUNE SYSTEM; MEMBRANE GLYCOPROTEINS; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; VIRUS REPLICATION;

EID: 0036932579     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202320935429     Document Type: Article

References (17)

1. Plaeger S, Bass HZ, Nishanian P, Thomas J, Aziz N, Detels R, King J, Cumberland W, Kemeny M, and Fahey JL: The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes. Clin Immunol 1999;90:238-246.
2. Aukrust P, Muller F, Lien E, Nordoy I, Liabakk NB, Kvale D, Espevik T, and Froland SS: Tumor necrosis factor (TNF) system levels in human immunodeficiency virus infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 1999;79:74-82.
3. De Milito A, Hejdeman B, Albert J, Aleman S, Sonnerborg A, Zazzi M, and Chiodi F: High plasma levels of soluble Fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2000;16:1379-1384.
4. Giovannetti A, Ensoli F, Mazzetta M, De Cristofaro M, Pierdominici M, Miratori DS, Fiorelli V, and Aiuti F: CCR5 and CXCR4 chemokine receptor expression and β-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy. Clin Exp Immunol 1999;118:87-94.
5. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, Price P, Flexman JP, and Tay-Kearney ML: Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000;1:107-115.
6. De Simone JA, Pomerantz RJ, and Babinchak TJ: Inflammatory reactions in HIV-1 infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000;133:447-454.
7. French MA and Price P: Immune restoration disease in HIV patients: Aberrant immune responses after antiretroviral therapy. J HIV Ther 2002;7:46-51.
8. Stone S, Price P, Keane NM, Murray R, and French MA: Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med 2002;3:21-27.
9. Stone SF, Price P, Brochier J, and French MA: Plasma bioavailable interleukin-6 is increased in human immunodeficiency virusinfected patients who experience herpesvirus-associated immune restoration disease after start of HAART. J Infect Dis 2001;184:1073-1077.
10. Stone SF, Price P, Tay-Kearney M-L, and French MA: Cytomegalovirus (CMV) retinitis immune restoration disease occurs during HAART-induced restoration of CMV specific immune responses within a predominant T2 cytokine environment. J Infect Dis 2002;185:1813-1817.
11. Price P, Mathiot N, Krueger R, Stone S, Keane NM, and French MA: Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J Clin Virol 2001 ;22:279-287.
12. McCloskey JC, Chaney R, Latham B, Flexman J, Hall J, and French M: Extensive perianal and anal canal intraepithelial neoplasia (AIN) in an HIV antibody positive male treated with combination antiretroviral therapy. In 4th International Multidisciplinary Congress EUROGIN, Paris, France, April 5-9, 2000. Monduzzi, Bologne, Italy, pp. 385-389.
13. Hassell M and French MA: Mycobacterium avium infection and immune restoration disease after highly active antiretroviral therapy in a patient with HIV and normal CD4+ counts. Eur J Clin Microbiol Infect Dis 2001;20:889-891.
14. Kreuzer KA, Dayer JM, Rockstroh JK, Sauerbruch T, and Spengler U: The IL-1 system in HIV infection: Peripheral concentrations of IL-1β, IL-1 receptor antagonist, and soluble IL-1 receptor type II. Clin Exp Immunol 1997;109:54-58.
15. Leng Q, Borkow G, Weisman Z, Stein M, Kalinkovich A, and Bentwich Z: Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. J Acquir Immune Defic Syndr 2001;27:389-397.
16. Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S, and Cooper D for the OzCombo 1 Study Group: A randomised, open label comparison of three highly active antiretroviral therapy (HAART) regimens including indinavir for previously untreated HIV-1 infection: The OzCombo 1 study. AIDS 2000;14: 1171-1180.
17. Cohen Stuart JW, Hazebergh MD, Hamann D, Otto SA, Borleffs JC, Miedema F, Boucher CA, and de Boer RJ: The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr 2000;25:203-211.